Biosimilars in paediatric inflammatory bowel disease

Area of Science:

• Gastroenterology
• Immunology
• Pharmacology

Background:

• Biological treatments have transformed inflammatory bowel disease (IBD) management, offering high efficacy for inducing and maintaining remission.
• A
• Biological therapies, while effective, are costly, leading to premature treatment cessation and potential disease exacerbation.
• The development of anti-drug antibodies can cause treatment failure and adverse reactions.

Purpose of the Study:

• To evaluate the role and impact of biological biosimilars in inflammatory bowel disease treatment.
• To assess the cost-effectiveness and patient adherence associated with biosimilar therapies.
• To analyze the efficacy and safety profiles of biosimilar infliximab compared to reference infliximab.

Main Methods:

• Review of pediatric data on biosimilar infliximab use.
• Comparative analysis of efficacy and safety between biosimilar and reference infliximab.
• Examination of cost-reduction data associated with biosimilar adoption.

Main Results:

• Biosimilar infliximabs demonstrate comparable efficacy to reference infliximab in pediatric patients.
• Safety profiles of biosimilar and reference infliximab appear similar.
• Pediatric data suggests potential cost reductions of 10%-30% with biosimilar use.

Conclusions:

• Biological biosimilars offer a promising avenue to reduce therapy costs and improve patient access to effective IBD treatments.
• Biosimilars may help prevent premature treatment termination, thereby improving long-term disease management.
• The findings support the use of biosimilar infliximab as a cost-effective alternative with similar efficacy and safety.